Patricia L Winokur
Overview
Explore the profile of Patricia L Winokur including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
676
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang B, Fong Y, Dang L, Fintzi J, Chen S, Wang J, et al.
Nat Commun
. 2025 Jan;
16(1):759.
PMID: 39824819
Neutralizing antibody titer has been a surrogate endpoint for guiding COVID-19 vaccine approval and use, although the pandemic's evolution and the introduction of variant-adapted vaccine boosters raise questions as to...
2.
El Sahly H, Anderson E, Jackson L, Neuzil K, Atmar R, Bernstein D, et al.
Vaccine
. 2025 Jan;
47:126689.
PMID: 39756216
Introduction: Pandemic influenza vaccine development focuses on the hemagglutinin (HA) antigen for potency and immunogenicity. Antibody responses targeting the neuraminidase (NA) antigen, or the HA stalk domain have been implicated...
3.
Boutzoukas A, Balevic S, Hemmersbach-Miller M, Winokur P, Gu K, Chan A, et al.
Clin Pharmacokinet
. 2024 Dec;
64(2):229-241.
PMID: 39681779
Background And Objective: We conducted an opportunistic pharmacokinetic study to evaluate the population pharmacokinetics of meropenem, an antimicrobial commonly used to treat Gram-negative infections in adults of different ages, including...
4.
Fong Y, Dang L, Zhang B, Fintzi J, Chen S, Wang J, et al.
Clin Infect Dis
. 2024 Sep;
80(1):223-227.
PMID: 39325506
For COVAIL recipients of a coronavirus disease 2019 (COVID-19) Sanofi booster vaccine, neutralizing antibody titers were assessed as a correlate of risk (CoR) of COVID-19. Peak and exposure-proximal titers were...
5.
Xiang J, Katz L, Winokur P, Chaudhary A, Digmann B, Bradford R, et al.
J Immunol Methods
. 2024 Jun;
530:113698.
PMID: 38823574
There is a critical need to understand the effectiveness of serum elicited by different SARS-CoV-2 vaccines against SARS-CoV-2 variants. We describe the generation of reference reagents comprised of post-vaccination sera...
6.
Jackson L, Stapleton J, Walter E, Chen W, Rouphael N, Anderson E, et al.
Vaccine
. 2023 Dec;
42(2):295-309.
PMID: 38105137
Background: Human infections with the avian influenza A(H7N9) virus were first reported in China in 2013 and continued to occur in annual waves. In the 2016/2017 fifth wave, Yangtze River...
7.
Branche A, Rouphael N, Diemert D, Falsey A, Losada C, Baden L, et al.
Nat Med
. 2023 Aug;
29(9):2334-2346.
PMID: 37640860
Vaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection wanes over time, requiring updated boosters. In a phase 2, open-label, randomized clinical trial with sequentially enrolled stages at...
8.
Rouphael N, Branche A, Diemert D, Falsey A, Losada C, Baden L, et al.
J Infect Dis
. 2023 Aug;
228(12):1662-1666.
PMID: 37561027
We compared the serologic responses of 1 dose versus 2 doses of a variant vaccine (Moderna mRNA-1273 Beta/Omicron BA.1 bivalent vaccine) in adults. A 2-dose boosting regimen with a variant...
9.
Rouphael N, Branche A, Diemert D, Falsey A, Losada C, Baden L, et al.
medRxiv
. 2023 Jun;
PMID: 37333252
In this brief report, we compare the magnitude and durability of the serologic response of one versus two doses (separated by 56 days) of a variant vaccine (Moderna mRNA-1273 Beta/Omicron...
10.
Comellas A, Wangui-Verry J, Sprenger K, Winokur P, Barlow P, Subramain M
J Clin Transl Sci
. 2023 May;
7(1):e89.
PMID: 37125056
The clinical research units (CRUs) are one of the main spaces where both translational research and science take place. However, there is a lack of information about both best practices...